Details of the Drug

General Information of Drug (ID: DMUY35B)

Drug Name

Progesterone

Synonyms

progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite; LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine

Indication

Disease Entry	ICD 11	Status	REF
Amenorrhea	GA20.0	Approved	[1]
Hot flushes	GA30	Approved	[2]
Premature labour	JB00	Approved	[3]
Contraception	QA21	Phase 3	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1	[5]
Endometrial carcinoma	N.A.	Investigative	[2]
Endometriosis	GA10	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

314.5

Logarithm of the Partition Coefficient (xlogp)

3.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Elimination: 0% of drug is excreted from urine in the unchanged form [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 21.19955 micromolar/kg/day [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.007 mg/mL [6]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Blood luteinising hormone increased	Not Available	LHCGR	OTSVIJ6I	[8]
Hormone level abnormal	Not Available	RBP1	OTRP1MFC	[8]
Leiomyoma	Not Available	WNT1 INT1	OTULVPZW	[8]
Leiomyoma	Not Available	CTNNB1 CTNNB OK/SW-cl.35 PRO2286	OTZ932A3	[8]
Reticuloendothelial disorders NEC	Not Available	PRKCA PKCA PRKACA	OT5UWNRD	[8]
Reticuloendothelial disorders NEC	Not Available	SLC7A1 ATRC1 ERR REC1L	OTR2ZVA8	[8]
-----------


⏷ Show the Full List of 6 ADR Information of This Drug

Chemical Identifiers

Formula: C21H30O2
IUPAC Name: (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
InChI: InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
InChIKey: RJKFOVLPORLFTN-LEKSSAKUSA-N

Cross-matching ID

PubChem CID: 5994
ChEBI ID: CHEBI:17026
CAS Number: 57-83-0
DrugBank ID: DB00396
TTD ID: D07BSQ
VARIDT ID: DR00281
INTEDE ID: DR1346
ACDINA ID: D00560

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Progesterone receptor (PGR)	TTUV8G9	PRGR_HUMAN	Agonist	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[13]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[15]
Glutathione S-transferase alpha-1 (GSTA1)	DE4ZHS1	GSTA1_HUMAN	Substrate	[16]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[14]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[18]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[19]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[20]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[21]
Cytochrome P450 4B1 (CYP4B1)	DEMF740	CP4B1_HUMAN	Substrate	[22]
Cholesterol 24-hydroxylase (CYP46A1)	DEKP5HX	CP46A_HUMAN	Substrate	[23]
Aldo-keto reductase 1C1 (AKR1C1)	DE7P2FB	AK1C1_HUMAN	Substrate	[24]
Steroid 21-hydroxylase (CYP21A2)	DE0JMZ5	CP21A_HUMAN	Substrate	[25]
Cytochrome P450 MEG (cyp106)	DEZ1H4L	CPXM_BACME	Substrate	[26]
Cytochrome P450 21A2 (cyp21)	DEBY951	A0A250VKS1_STROL	Substrate	[27], [28]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (ABHD5)	OTY829Z3	ABHD5_HUMAN	Gene/Protein Processing	[29]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Gene/Protein Processing	[29]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1 (PLCH1)	OT6Z1L2E	PLCH1_HUMAN	Gene/Protein Processing	[30]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Gene/Protein Processing	[30]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[31]
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)	OT3K7HY5	DHB2_HUMAN	Gene/Protein Processing	[32]
2'-5'-oligoadenylate synthase 1 (OAS1)	OT8ZLOCY	OAS1_HUMAN	Gene/Protein Processing	[33]
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1)	OTTK98BH	CP27B_HUMAN	Gene/Protein Processing	[34]
28 kDa heat- and acid-stable phosphoprotein (PDAP1)	OTJSWMOD	HAP28_HUMAN	Gene/Protein Processing	[35]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1)	OTNAZVKB	3BHS1_HUMAN	Biotransformations	[36]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Progesterone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Progesterone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[37]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[38]
Daunorubicin	DMQUSBT	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Daunorubicin.	Acute myeloid leukaemia [2A60]	[38]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Progesterone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[37]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Progesterone caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[37]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Progesterone caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[39]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Progesterone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[40]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Progesterone caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[41]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Progesterone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[41]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Progesterone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[42]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Progesterone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[43]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Progesterone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[44]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Progesterone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[37]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Progesterone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[45]
Atorvastatin	DMF28YC	Minor	Decreased metabolism of Progesterone caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[46]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Progesterone caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[37]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Progesterone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[37]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Progesterone due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[43]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Progesterone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[43]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Progesterone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[40]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Progesterone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[43]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Progesterone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[47]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Progesterone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Griseofulvin	DMK54YG	Moderate	Increased metabolism of Progesterone caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[37]
Primidone	DM0WX6I	Moderate	Increased metabolism of Progesterone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Progesterone caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Progesterone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Progesterone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Progesterone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[49]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Progesterone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Progesterone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[50]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Progesterone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Progesterone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Progesterone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Progesterone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[51]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Progesterone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[41]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Progesterone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[41]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Progesterone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[41]
Ripretinib	DM958QB	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[43]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Progesterone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[37]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Progesterone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[52]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Progesterone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[53]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Progesterone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[40]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Progesterone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[37]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[54]
Delavirdine	DM3NF5G	Minor	Decreased metabolism of Progesterone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Progesterone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Progesterone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Progesterone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Progesterone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[58]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Progesterone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[59]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Progesterone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[37]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Progesterone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[60]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Progesterone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[37]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Progesterone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[50]
GDC-0199	DMH0QKA	Major	Decreased clearance of Progesterone due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[43]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Progesterone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[61]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[43]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Progesterone caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[37]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Progesterone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[37]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Progesterone caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[62]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Progesterone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[37]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Progesterone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[50]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Progesterone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[63]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Progesterone caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[64]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Progesterone caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[65]
Modafinil	DMYILBE	Minor	Increased metabolism of Progesterone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[66]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Progesterone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[67]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Progesterone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[68]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Progesterone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[69]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Progesterone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[70]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Progesterone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[37]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Progesterone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[37]
Riociguat	DMXBLMP	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[43]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Progesterone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[71]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Progesterone caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[37]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Progesterone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[50]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Progesterone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[43]
Armodafinil	DMGB035	Minor	Increased metabolism of Progesterone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[66]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[72]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[67]
Apixaban	DM89JLN	Moderate	Decreased clearance of Progesterone due to the transporter inhibition by Apixaban.	Thrombosis [DB61-GB90]	[50]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Progesterone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[71]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Progesterone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[71]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Progesterone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[37]
-----------


⏷ Show the Full List of 85 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Soybean lecithin	E00637	Not Available	Other agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Progesterone 100 mg capsule	100 mg	Oral Capsule	Oral
Progesterone 200 mg capsule	200 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075906.
2	Progesterone FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2377).
4	ClinicalTrials.gov (NCT00822900) Progesterone for the Treatment of Traumatic Brain Injury III. U.S. National Institutes of Health.
5	ClinicalTrials.gov (NCT04365127) Progesterone for the Treatment of COVID-19 in Hospitalized Men. U.S. National Institutes of Health.
6	BDDCS applied to over 900 drugs
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9	Clinical pipeline report, company report or official report of lipocine.
10	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
11	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
12	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
14	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
15	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
16	Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
17	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
18	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
19	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
20	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
21	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
22	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160-6.
23	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
24	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
25	Human cytochrome P450 21A2, the major steroid 21-hydroxylase: structure of the enzyme progesterone substrate complex and rate-limiting C-H bond cleavage. J Biol Chem. 2015 May 22;290(21):13128-43.
26	Engineering of CYP106A2 for steroid 9alpha- and 6beta-hydroxylation. Steroids. 2017 Apr;120:41-48.
27	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
28	A Novel NADPH-dependent flavoprotein reductase from Bacillus megaterium acts as an efficient cytochrome P450 reductase. J Biotechnol. 2016 Aug 10;231:83-94.
29	Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
30	Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
31	Effect of the interaction between lipoxygenase pathway and progesterone on the regulation of hydroxysteroid 11-Beta dehydrogenase 2 in cultured human term placental trophoblasts. Biol Reprod. 2008 Mar;78(3):514-20.
32	Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
33	Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol. 2011 Aug 15;187(4):1778-87. doi: 10.4049/jimmunol.1003919. Epub 2011 Jul 18.
34	Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
35	Elucidating progesterone effects in breast cancer: cross talk with PDGF signaling pathway in smooth muscle cell. J Cell Biochem. 2007 Jan 1;100(1):174-83. doi: 10.1002/jcb.21045.
36	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
37	Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
38	Multum Information Services, Inc. Expert Review Panel.
39	Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
40	Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
41	Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
42	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
43	Cerner Multum, Inc. "Australian Product Information.".
44	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
45	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
47	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
48	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
49	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
50	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
52	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
53	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
54	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
55	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
56	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
57	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
58	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
59	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
60	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
61	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
62	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
63	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
64	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
65	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
66	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
67	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
68	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
69	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
70	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
71	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
72	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.